Analyst firms · Morgan Stanley · BSX

Morgan Stanley BSX price target and rating history

Boston Scientific Corporation (BSX) · Health Care

Morgan Stanley rates Boston Scientific Corporation (BSX) Overweight with a $58 price target, as of its latest action on May 30, 2023. It has published 3 rating actions on BSX since July 2021, including 0 upgrades and 0 downgrades. Across 5 firms with a BSX price target in the last 12 months, the median target is $50.

Current rating
Overweight
Price target
$58
Median target, all firms
$50
Actions on BSX
3

Morgan Stanley price target on BSX

$58$55$5120222023202420252026
Morgan Stanley price target on BSX, each point a stated target, July 2021 to May 2023.

Every Morgan Stanley rating on BSX

How other firms rate BSX

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
TD CowenHold$46Oct 30, 2026
OppenheimerPerformOct 29, 2026
BarclaysEqual Weight$48Oct 7, 2026
CitigroupNeutral$50Sep 17, 2026
Argus ResearchHoldJul 31, 2026
Wolfe ResearchPeer PerformMay 29, 2026
Wells FargoEqual Weight$55May 28, 2026
Raymond JamesOutperform$88Mar 30, 2026

Questions about Morgan Stanley and BSX

What is Morgan Stanley's price target for BSX?
Morgan Stanley's latest stated price target for Boston Scientific Corporation (BSX) is $58, from its action on May 30, 2023.
What is Morgan Stanley's rating on BSX?
Morgan Stanley rates BSX Overweight, a bullish rating, as of May 30, 2023.
When did Morgan Stanley last change its view on BSX?
On May 30, 2023, Morgan Stanley resumes coverage at Overweight, price target $58.
How does Morgan Stanley's BSX target compare with other analysts?
Across 5 firms with a BSX price target in the last 12 months, the median target is $50.

More BSX rating histories

All Morgan Stanley ratingsBSX news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.